Factor X Launches RNA Skin Longevity Platform

A new player, FACTOR X, has officially emerged from stealth mode, introducing a sophisticated RNA-based platform aimed at revolutionizing the skincare industry by targeting cellular longevity. This innovative venture, co-founded by entrepreneur Bar Refaeli, longevity physician Dr. Inbal Gat, Harvard-trained scientist Dr. Shira Orr, and health-tech executive Eran Orr, is developing a proprietary delivery system designed to transport biological payloads directly into skin cells. The company's ambition is to shift the paradigm from superficial cosmetic treatments to deep cellular rejuvenation, addressing the biological aging processes from within.

The core of FACTOR X's technology lies in a unique nanoparticle engineered to protect RNA molecules and facilitate their penetration into targeted skin cells. Once inside, the RNA can instruct cells to resume functions characteristic of younger skin. Potential applications are extensive, ranging from boosting natural hyaluronic acid synthesis in mature skin and restoring hair pigmentation to reactivating dormant hair follicles and correcting age-related cellular damage. This approach moves beyond traditional topical applications, which often struggle to reach the deeper layers of the dermis where cellular activity is most critical.

Dr. Inbal Gat, who leads the company's clinical vision, brings a wealth of experience from over a decade in aesthetic medicine and specialized training in longevity medicine. Her philosophy, termed "Skin Longevity," emphasizes internal cellular repair over external masking. Complementing her expertise, Dr. Shira Orr, as Chief Scientific Officer, is spearheading the development of the nanoparticle delivery system, building on her postdoctoral research at Harvard University. The team also benefits from Bar Refaeli's extensive global brand experience and market access, alongside Eran Orr's proven track record in scaling health technology ventures, notably with XRHealth.

FACTOR X has already secured pre-seed funding and is actively raising a seed round to fuel its product development and operational expansion. Initial plans include establishing laboratory facilities in Israel, while continuing research collaborations in Boston. The company's platform is designed for safety and ease of integration, boasting non-toxicity, room-temperature stability as a powder, and compatibility with existing cosmetic formulations. This makes it an attractive proposition for established beauty brands looking to incorporate advanced cellular technology into their product lines.

The strategic B2B model allows FACTOR X to partner with major cosmetics companies, offering its technology for integration into serums, creams, and masks. This approach aims to democratize access to cutting-edge longevity science within the beauty sector. The company envisions creating a new market category: "Real Skin Longevity." The global skincare market, valued at over $150 billion, is increasingly driven by demand for scientifically backed, results-oriented products, making FACTOR X's cellular-level approach particularly timely.

Early proof-of-concept studies have demonstrated the technological feasibility of the platform. By enabling targeted cells like fibroblasts to produce youthful proteins, FACTOR X aims to deliver tangible anti-aging effects. The company is actively pursuing strategic partnerships to accelerate its go-to-market strategy and establish its innovative technology as a cornerstone of future beauty and consumer biotechnology advancements.